ADAPT Forward2NCT07673627
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 14 → 19 locations
- Minor Trial sites expanded: 8 → 14 locations
- Minor Trial sites expanded: 4 → 8 locations
- Minor Site details revised at 1 of 4 sites
- Notable Eligibility criteria expanded, about 7 words
- Study sites: 3 to 4
- Secondary endpoints: details revised at 7 of 9 entries
- Minor Study sites: 2 to 3v3
- Notable Recruitment opened
- Study sites: 0 to 2
- Start date changed from estimate of Jun 29, 2026 to Jul 10, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of adverse events and serious adverse events in the DBTP
Timeframe: Up to 12 weeks
Secondary (9)
MG-ADL total score change from baseline at week 12
QMG total score change from baseline at week 12
MG-ADL total score change from baseline over time up to week 12
QMG total score change from baseline over time up to week 12
Proportion of participants reaching MSE at any point by week 12
Show 4 moreShow less
Proportion of participants who have ≥3-point reduction in MG-ADL at week 12
Proportion of participants who have ≥5-point reduction in QMG at week 12
Proportion of participants who have a positive PASS at week 12
Proportion of participants who have a 50% MG-ADL total score improvement at week 12
Arms and interventions
Empasiprubart IVExperimental
Participants receive empasiprubart IV in the DBTP
Placebo IVPlacebo comparator
Participants receive placebo IV in the DBTP
Efgartigimod PH20 SC PFSOther
Participants receive open-label efgartigimod PH20 SC PFS in the safety follow-up period
Biologicals: Empasiprubart IV
Other: Placebo IV
Combination products: Efgartigimod PH20 SC PFS
Sites
19 sites in 7 countries
United States 7, Italy 4, Greece 2, Japan 2, Spain 2, Belgium 1, Netherlands 1